

# Atsuyuki Igarashi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5221282/publications.pdf>

Version: 2024-02-01

26  
papers

930  
citations

687363

13  
h-index

642732

23  
g-index

26  
all docs

26  
docs citations

26  
times ranked

1008  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Efficacy and safety of ustekinumab in Japanese patients with moderate to severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial. <i>Journal of Dermatology</i> , 2012, 39, 242-252.   | 1.2 | 180       |
| 2  | Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 823-831. | 1.2 | 159       |
| 3  | Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study. <i>Journal of Dermatology</i> , 2016, 43, 869-880.  | 1.2 | 79        |
| 4  | Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1575-1583.  | 2.9 | 73        |
| 5  | Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the Susta-IMM phase 2/3 trial. <i>Journal of Dermatology</i> , 2019, 46, 686-694.  | 1.2 | 70        |
| 6  | Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis. <i>Journal of Dermatology</i> , 2020, 47, 114-120.   | 1.2 | 65        |
| 7  | Japanese guidance for use of biologics for psoriasis (the 2019 version). <i>Journal of Dermatology</i> , 2020, 47, 201-222.  | 1.2 | 58        |
| 8  | Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 854-862.   | 1.2 | 56        |
| 9  | Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria. <i>Journal of Dermatological Science</i> , 2017, 87, 70-78.   | 1.9 | 49        |
| 10 | Long-term efficacy and safety results from an open-label phase III study ( UNCOVER 4) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 568-576.                        | 2.4 | 23        |
| 11 | Prevalence and current therapies of psoriatic arthritis in Japan: A survey by the Japanese Society of Psoriasis Research in 2016. <i>Journal of Dermatology</i> , 2017, 44, e121.  | 1.2 | 18        |
| 12 | Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan. <i>Journal of Dermatological Treatment</i> , 2013, 24, 351-355.  | 2.2 | 17        |
| 13 | Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies. <i>Dermatology and Therapy</i> , 2021, 11, 971-982.   | 3.0 | 17        |
| 14 | Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch. <i>Journal of Dermatology</i> , 2017, 44, 1105-1111.  | 1.2 | 13        |
| 15 | Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study. <i>Allergology International</i> , 2018, 67, 243-252.  | 3.3 | 13        |
| 16 | Twelve-week, multicenter, placebo-controlled, randomized, double-blind, parallel-group, comparative phase II/III study of benzoyl peroxide gel in patients with acne vulgaris: A secondary publication. <i>Journal of Dermatology</i> , 2017, 44, 774-782.   | 1.2 | 9         |
| 17 | Late-onset psoriatic arthritis in Japanese patients. <i>Journal of Dermatology</i> , 2019, 46, 169-170.  | 1.2 | 8         |
| 18 | Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1). <i>Journal of Dermatology</i> , 2021, 48, 844-852.   | 1.2 | 6         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective. <i>Journal of Medical Economics</i> , 2019, 22, 7-15.   | 2.1 | 5         |
| 20 | Switching biologics in the treatment of psoriatic arthritis in Japan. <i>Journal of Dermatology</i> , 2019, 46, e113-e114.  | 1.2 | 4         |
| 21 | Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1). <i>Journal of Dermatology</i> , 2021, 48, 853-863.    | 1.2 | 4         |
| 22 | Juvenile-onset psoriatic arthritis: a survey by the Japanese Society for Psoriasis Research. <i>European Journal of Dermatology</i> , 2018, 28, 419-421.  | 0.6 | 3         |
| 23 | Clinical use of the topical nail liquid efinaconazole in 484 patients with onychomycosis including long-term cases.. <i>Journal of the Japan Organization of Clinical Dermatologists</i> , 2018, 35, 748-752. | 0.0 | 1         |
| 24 | Efficacy of a topical combination drug containing calcipotriol hydrate and betamethasone dipropionate for psoriasis. <i>Journal of the Japan Organization of Clinical Dermatologists</i> , 2017, 34, 462-467. | 0.0 | 0         |
| 25 | Subanalysis of Efficacy by Body Region and Sign and Safety by Body Region of Delgocitinib Ointment. <i>Journal of the Japan Organization of Clinical Dermatologists</i> , 2021, 38, 898-905.                  | 0.0 | 0         |
| 26 | English version of guidelines for the management of asteatosis 2021 in Japan. <i>Journal of Dermatology</i> , 2022, 49, .   | 1.2 | 0         |